Evidence map›Paper›PMID 37492565›Full record

ReviewFrontiers in immunology2023

Janus kinase inhibitors in autoimmune bullous diseases.

Dawei Huang, Yuexin Zhang, Luyang Kong, Jiajing Lu, Yuling Shi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Bullous pemphigoid.Nature reviews. Disease primers · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dawei HuangDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Yuexin ZhangDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Luyang KongDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Jiajing LuDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Yuling ShiDepartment of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Shanghai Skin Disease Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants. Additionally, the utilization of biological agents such as rituximab, omalizumab, and dupilumab is on the rise. However, effectively managing AIBD remains a challenge. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway has been implicated in various inflammatory diseases. In recent years, a range of drugs known as JAK inhibitors, which target this pathway, have been developed. Several studies have explored the efficacy and safety of JAK inhibitors for treating AIBD. Consequently, this review begins by examining the role of the JAK/STAT pathway in AIBD, summarizing the application of different JAK inhibitors in AIBD treatment, and emphasizing the importance of disease management in treating AIBD with JAK inhibitors. Furthermore, it highlights the need for a better understanding of the JAK/STAT pathway's role in AIBD, as well as the effectiveness and safety of JAK inhibitors for treating this disease.

Indexed as

Autoimmune DiseasesJanus Kinase InhibitorsSkin Diseases, VesiculobullousHumansJanus KinasesSignal TransductionSTAT Transcription FactorsJanus Kinase InhibitorsJanus KinasesSTAT Transcription Factorsautoimmune bullous diseaseJAK-STAT signaling pathwayJanus kinase inhibitorpemphigoidpemphigus

Identifiers

PMID37492565
PMCPMC10363722
OpenAlexW4383721338

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.